X
[{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S\u2011217622","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Ensitrelvir
Filters
Companies By Therapeutic Area
The AIDS Clinical Trials Group
Details:
FDA has cleared the IND for S-217622, a once-daily investigational 3CL protease inhibitor oral antiviral therapy, enabling the global phase 3 trial to proceed as part of the ACTIV-2 program for COVID-19.
Lead Product(s):
Ensitrelvir
Therapeutic Area: Infections and Infectious Diseases
Product Name: S-217622
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shionogi
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 16, 2022
Details:
S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease, an orally administered antiviral drug for COVID-19, caused by the novel coronavirus (SARS-CoV-2).
Lead Product(s):
Ensitrelvir
Therapeutic Area: Infections and Infectious Diseases
Product Name: S-217622
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 21, 2021